Tranylcypromine-agomelatine

From Psychiatrienet
Revision as of 14:41, 5 October 2015 by Anoek (talk | contribs)
Jump to: navigation, search
Tranylcypromine
Type Antidepressant
Group MAO-I
links
Medscape Tranylcypromine
PubChem 5530
PubMed Tranylcypromine
Kompas (Dutch) Tranylcypromine
Wikipedia Tranylcypromine
Agomelatine
Type Antidepressant
Group other
links
ATC-code N06AX22
EMEA valdoxan
PubChem 82148
PubMed Agomelatine
Kompas (Dutch) Agomelatine
Wikipedia Agomelatine

Switch medication from tranylcypromine to agomelatine.[1] [2]

Nietinrijdenbord.png Stop tranylcypromine
  • Before day 1: gradually reduce dosage of tranylcypromine to a maximum of 40 mg/day, when this dosage is > 40 mg/day.
  • Day 1: reduce dosage of tranylcypromine to 20 mg/day.
  • Day 8: reduce dosage of tranylcypromine to 10 mg/day.
  • Day 15: stop administration of tranylcypromine.
Eenrichtingbord.png Start agomelatine
  • Day 15-28: a wash-out period of two weeks is necessary.
  • Day 29: start administration of agomelatine in a dosage of 25 mg/day.
  • If necessary, increase dosage of agomelatine to 50 mg/day.
Infobord.png More information
  • Tranylcypromine has to be phased out to avoid withdrawal symptoms.
  • Because tranylcypromine is a irrivesible MAO inhibitor, the activity of MAO enzymes will be normal again after two weeks.
  • Occurrence of the serotonin syndrome is possible without a wash-out period.
  • This switch is currently being reviewed.
  1. Switches are based on literature references on this page and expert opinions of the authors. The authors have used pharmacokinetic and receptor affinity properties to determine the switch schedules
  2. Stahl, S. M. (2013). Stahl's essential psychopharmacology: Neuroscientific basis and practical applications (4th ed.). Cambridge University Press.
The editors of psychiatrienet.nl take the greatest care to provide up-to-date and accurate information on this site. Nevertheless, mistakes and omissions cannot be entirely excluded. No rights devolve from the information provided. The editors and other providers of information to this site accept no responsibility for the content of this site or for the information provided therein; neither do they accept responsibility for possible damages which may derive from the use of the information on this site or from the linked sites. The editorial board accepts no responsibility for the content of the (linked) sites, for access to them, or for the products and services on these sites, nor for the occurrence of errors, viruses, and/or disruptions in service.